Cargando…
The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study
Background: Emulsified isoflurane is a novel intravenous general anesthetic obtained by encapsulating isoflurane molecules into emulsion. The formulation of emulsion has been improved according to the latest regulations of the China Food and Drug Administration. This study was designed to compare th...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988084/ https://www.ncbi.nlm.nih.gov/pubmed/33776768 http://dx.doi.org/10.3389/fphar.2021.626307 |
_version_ | 1783668719837249536 |
---|---|
author | Yang, Hui Yin, Qinqin Huang, Luying Zhang, Min Zhang, Xinxin Sun, Qirong Liu, Xuewei Wang, Qi Yang, Xi Tan, Lingcan Ye, Mao Liu, Jin |
author_facet | Yang, Hui Yin, Qinqin Huang, Luying Zhang, Min Zhang, Xinxin Sun, Qirong Liu, Xuewei Wang, Qi Yang, Xi Tan, Lingcan Ye, Mao Liu, Jin |
author_sort | Yang, Hui |
collection | PubMed |
description | Background: Emulsified isoflurane is a novel intravenous general anesthetic obtained by encapsulating isoflurane molecules into emulsion. The formulation of emulsion has been improved according to the latest regulations of the China Food and Drug Administration. This study was designed to compare the bioequivalence of the new and previous formulation emulsion of isoflurane. Methods: In a single-center, single-dose, double-blinded, randomized, two-period crossover study, healthy volunteers received intravenous injection of 30 mg/kg of isoflurane with either previous formulation of emulsion isoflurane (PFEI) or new formulation of emulsion isoflurane (NFEI). Arterial and venous blood samples were obtained for geometric mean test/reference ratios of C(max), AUC(0-t), and AUC(0-∞,) as well as their 90% confidence interval (CI90) as the primary outcome. The secondary outcomes were safety measurements such as vital signs, 12-lead electrocardiography, adverse effects, and laboratory tests; and anesthesia efficacy was assessed by Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score, bispectral index (BIS), and loss/recovery of eyelash reflex. Results: 24 subjects were eligible, of which 21 completed the whole experiment (NFEI n = 21, PFEI n = 23). Arterial geometric mean test/reference ratios of C(max), AUC(0-t), and AUC(0-∞) were 104.50% (CI90 92.81%–117.65%), 108.23% (94.51%–123.96%), and 106.53% (93.94%∼120.80%), respectively. The most commonly seen adverse effects for NFEI and PFEI were injection pain (38.1% vs. 34.8%), hypotension (19.0% vs. 13.0%), apnea (14.3% vs. 17.4%), and upper airway obstruction (14.3% vs. 13.0%). No severe adverse effect was observed. The effectiveness of general anesthesia was similar between the two formulations. Conclusion: The CI90 of C(max), AUC(0-t), AUC(0-∞), NFEI, and PFEI were within the range of 80%–125%, suggesting bioequivalence between NFEI and PFEI. The safety and anesthesia effectiveness were also similar. |
format | Online Article Text |
id | pubmed-7988084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79880842021-03-25 The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study Yang, Hui Yin, Qinqin Huang, Luying Zhang, Min Zhang, Xinxin Sun, Qirong Liu, Xuewei Wang, Qi Yang, Xi Tan, Lingcan Ye, Mao Liu, Jin Front Pharmacol Pharmacology Background: Emulsified isoflurane is a novel intravenous general anesthetic obtained by encapsulating isoflurane molecules into emulsion. The formulation of emulsion has been improved according to the latest regulations of the China Food and Drug Administration. This study was designed to compare the bioequivalence of the new and previous formulation emulsion of isoflurane. Methods: In a single-center, single-dose, double-blinded, randomized, two-period crossover study, healthy volunteers received intravenous injection of 30 mg/kg of isoflurane with either previous formulation of emulsion isoflurane (PFEI) or new formulation of emulsion isoflurane (NFEI). Arterial and venous blood samples were obtained for geometric mean test/reference ratios of C(max), AUC(0-t), and AUC(0-∞,) as well as their 90% confidence interval (CI90) as the primary outcome. The secondary outcomes were safety measurements such as vital signs, 12-lead electrocardiography, adverse effects, and laboratory tests; and anesthesia efficacy was assessed by Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score, bispectral index (BIS), and loss/recovery of eyelash reflex. Results: 24 subjects were eligible, of which 21 completed the whole experiment (NFEI n = 21, PFEI n = 23). Arterial geometric mean test/reference ratios of C(max), AUC(0-t), and AUC(0-∞) were 104.50% (CI90 92.81%–117.65%), 108.23% (94.51%–123.96%), and 106.53% (93.94%∼120.80%), respectively. The most commonly seen adverse effects for NFEI and PFEI were injection pain (38.1% vs. 34.8%), hypotension (19.0% vs. 13.0%), apnea (14.3% vs. 17.4%), and upper airway obstruction (14.3% vs. 13.0%). No severe adverse effect was observed. The effectiveness of general anesthesia was similar between the two formulations. Conclusion: The CI90 of C(max), AUC(0-t), AUC(0-∞), NFEI, and PFEI were within the range of 80%–125%, suggesting bioequivalence between NFEI and PFEI. The safety and anesthesia effectiveness were also similar. Frontiers Media S.A. 2021-03-10 /pmc/articles/PMC7988084/ /pubmed/33776768 http://dx.doi.org/10.3389/fphar.2021.626307 Text en Copyright © 2021 Yang, Yin, Huang, Zhang, Zhang, Sun, Liu, Wang, Yang, Tan, Ye and Liu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Yang, Hui Yin, Qinqin Huang, Luying Zhang, Min Zhang, Xinxin Sun, Qirong Liu, Xuewei Wang, Qi Yang, Xi Tan, Lingcan Ye, Mao Liu, Jin The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study |
title | The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study |
title_full | The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study |
title_fullStr | The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study |
title_full_unstemmed | The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study |
title_short | The Bioequivalence of Emulsified Isoflurane With a New Formulation of Emulsion: A Single-Center, Single-Dose, Double-Blinded, Randomized, Two-Period Crossover Study |
title_sort | bioequivalence of emulsified isoflurane with a new formulation of emulsion: a single-center, single-dose, double-blinded, randomized, two-period crossover study |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988084/ https://www.ncbi.nlm.nih.gov/pubmed/33776768 http://dx.doi.org/10.3389/fphar.2021.626307 |
work_keys_str_mv | AT yanghui thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT yinqinqin thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT huangluying thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT zhangmin thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT zhangxinxin thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT sunqirong thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT liuxuewei thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT wangqi thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT yangxi thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT tanlingcan thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT yemao thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT liujin thebioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT yanghui bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT yinqinqin bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT huangluying bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT zhangmin bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT zhangxinxin bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT sunqirong bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT liuxuewei bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT wangqi bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT yangxi bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT tanlingcan bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT yemao bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy AT liujin bioequivalenceofemulsifiedisofluranewithanewformulationofemulsionasinglecentersingledosedoubleblindedrandomizedtwoperiodcrossoverstudy |